Comparative effects of Yoshi-864 and busulfan on certain transplantable murine tumors.
Yoshi-864 extends markedly the survival times of mice bearing L1210 leukemia or Ehrlich ascites carcinoma. Busulfan, with methanesulfonate leaving groups identical with those of Yoshi-864, is without effect. Tumor cells from mice bearing the Ehrlich tumor and treated with Yoshi-864 have a persistent reduction in ability to synthesize DNA. Synthesis of DNA in cells from mice treated with busulfan is moderately suppresed at 48 hr after treatment, but returns virtually to the control value at 72 hr.
D000477:Alkylating Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002470:Cell Survival; D002642:Chick Embryo; D004261:DNA Replication / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007231:Infant, Newborn; D007274:Injections, Intraperitoneal; D007930:Leucine / Q000378:metabolism; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009368:Neoplasm Transplantation; D013936:Thymidine / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects; D014184:Transplantation, Homologous; D014316:Tritium; D014529:Uridine / Q000378:metabolism
D000477:Alkylating Agents; D009363:Neoplasm Proteins; D014316:Tritium; D002066:Busulfan; D007930:Leucine; D013936:Thymidine; D014529:Uridine